Recent Updates
Recently added Catalysts
CLDX Positive Sentiment

Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Wednesday, March 29, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Celldex Therapeutics, Inc. (NASDAQ:CLDX) will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30th. The company specializes in developing monoclonal and bispecific antibodies targeting inflammatory diseases and various forms of cancer. This event presents an opportunity for Celldex to discuss their pipeline and advancements with potential investors. A webcast of the presentation will be available, and a replay can be accessed for up to 90 days afterward.
Price reaction · baseline $34.78 (2023-03-28 close) · hit after-hours · clean, no other CLDX news in the window
day 0 close · peak
+3.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a significant virtual conference highlights visibility.
  • Opportunity to showcase innovative antibody-based therapeutics.
  • Engagement with the investment community during the fireside chat.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+77%
120-day peak, hindsight
Typical move
6.2%
average across 6 past catalysts
Cash runway
~37 mo
Minimal dilution risk
Lead asset
barzolvolimab
Phase 3 · Chronic Inducible Urticaria

Full Press Release Details

HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30th at 11:30 am ET. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.
Senior Vice President, Corporate Affairs & Administration

Frequently Asked Questions

When is Celldex's fireside chat at the conference?

The fireside chat will occur on March 30th at 11:30 am ET.

How can I watch the Celldex presentation?

You can view the webcast on the 'Events & Presentations' page of their website.

How long will the webcast replay be available?

The replay will be accessible for 90 days after the event.

What is Celldex Therapeutics focused on?

Celldex develops monoclonal and bispecific antibodies for inadequate treatments.

What types of diseases does Celldex target?

They target inflammatory diseases and various forms of cancer.

ShareAdd on Google
Tags: CLDX Viatris Investor Conferences Healthcare Celldex Therapeutics H.C. Wainwright autoimmune diseases biotechnology
Last updated: Mar 29, 2023

Biotech snapshot

Cash runway
$718M liquidity · $19M/mo burn
~37 mo
Minimal dilution risk
Lead asset
barzolvolimabPhase 3
Chronic Inducible Urticaria →

Catalyst track record

+77%
best trade around CLDX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CLDX.

See every catalyst's timing & PoA →